FDA clears Novo Nordisk (NYSE: NVO) Wegovy HD higher-dose obesity drug
Rhea-AI Filing Summary
Novo Nordisk reports that the US FDA has approved Wegovy® HD, a once-weekly injectable semaglutide 7.2 mg dose, to reduce excess body weight and maintain long-term weight reduction. The FDA also granted a Commissioner’s National Priority Voucher, highlighting the therapy’s importance for US health priorities.
The accelerated approval is supported by the STEP UP phase 3 programme. In the STEP UP trial in adults with obesity, semaglutide 7.2 mg delivered a 20.7% mean weight loss, and 31.2% of participants achieved at least 25% weight loss. In the STEP UP T2D trial in adults with obesity and type 2 diabetes, mean weight loss reached 14.1%. Safety and tolerability were consistent with the known profile of semaglutide.
Novo Nordisk plans to launch Wegovy® HD in a single-dose pen in the US in April 2026. The 7.2 mg dose is already approved for adults with obesity in the EU and UK, and regulatory decisions on the single-dose pen in those regions are expected in the second half of 2026.
Positive
- None.
Negative
- None.
Insights
FDA approval of higher-dose Wegovy HD strengthens Novo Nordisk’s obesity franchise with robust phase 3 weight-loss data.
The FDA approval of Wegovy® HD (semaglutide 7.2 mg) expands Novo Nordisk’s obesity treatment range beyond existing Wegovy doses and the newly launched pill. Support from the STEP UP programme, showing 20.7% mean weight loss in obesity, reinforces the clinical profile.
The Commissioner’s National Priority Voucher designation signals regulatory recognition of obesity as a critical US health challenge and highlights Wegovy HD’s perceived public-health relevance. In type 2 diabetes with obesity, the 14.1% mean weight loss suggests potential value in a large, complex patient segment.
Novo Nordisk expects a US launch in April 2026, with EU and UK single-dose pen decisions anticipated in the second half of 2026. Future disclosures in company communications and filings may clarify uptake, pricing dynamics and any capacity constraints as this higher-dose option rolls out alongside existing Wegovy and other semaglutide formulations.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did the FDA approve for Novo Nordisk (NVO) in this 6-K?
How effective is Wegovy HD according to the STEP UP trials for Novo Nordisk (NVO)?
When will Novo Nordisk (NVO) launch Wegovy HD in the United States?
What special recognition did the FDA give Wegovy HD from Novo Nordisk (NVO)?
How does Wegovy HD’s safety compare to earlier semaglutide trials for Novo Nordisk (NVO)?
Is Wegovy 7.2 mg already available outside the US for Novo Nordisk (NVO)?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
March 19, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss1
| · | Wegovy® HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight loss in the STEP UP trial |
| · | First US FDA approval of a GLP-1 treatment under the Commissioner’s National Priority Voucher pilot programme, for products addressing critical US national health priorities |
| · | Wegovy® HD complements Wegovy® 2.4 mg, which is already approved in the US for weight management and cardiovascular risk reduction |
| · | Novo Nordisk expects to launch Wegovy® HD in the US in April 2026 |
Bagsværd, Denmark, 19 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term. The FDA awarded a Commissioner’s National Priority Voucher for Wegovy® HD, accelerating its review and underscoring its potential to address critical patient needs and national health priorities in the US.
The accelerated approval is based on results from the STEP UP trial programme. In the STEP UP trial, semaglutide 7.2 mg injected once weekly demonstrated 20.7%1 mean weight loss in participants with obesity, and approximately one in three people experienced 25% or greater weight loss. In the STEP UP type 2 diabetes (T2D) trial, in participants with obesity and type 2 diabetes, semaglutide 7.2 mg demonstrated a mean weight loss of 14.1%1. In both trials, the well-known safety and tolerability profile of semaglutide was reaffirmed with semaglutide 7.2 mg, which was comparable to previous trials with semaglutide for weight management.
“Since its launch in 2021, Wegovy® has transformed the lives of many people living with obesity and helped them achieve meaningful weight loss and important cardiometabolic benefits, including an unprecedented reduction in cardiovascular risk,” said Mike Doustdar, president and CEO of Novo Nordisk. “Earlier this year, we launched the Wegovy® pill, and with the
___________________
1 Based on the efficacy estimand: treatment effect if all people adhered to treatment
accelerated approval of Wegovy® HD, we are introducing a new offering for our injectable semaglutide that provides even greater weight loss of approximately 21%. At Novo Nordisk, our goal is to provide innovative therapies that support healthier lives for people living with obesity, and we look forward to launching Wegovy® HD to help even more people reach their weight and health goals.”
Novo Nordisk expects to launch Wegovy® HD in a single-dose pen in the US in April 2026.
Wegovy® 7.2 mg is already approved for adults with obesity in the EU and the UK. Novo Nordisk expects regulatory decisions in the EU and the UK on semaglutide 7.2 mg in a single-dose pen in the second half of 2026.
About the STEP UP trials
The STEP UP and STEP UP T2D phase 3 trials investigated the efficacy and safety of injectable semaglutide 7.2 mg in people with obesity with or without type 2 diabetes.
The 72-week STEP UP trial evaluated the efficacy and safety of injectable semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included approximately 1,400 adults with obesity. The 72-week STEP UP T2D trial evaluated the efficacy and safety of injectable semaglutide 7.2 mg compared to placebo in approximately 500 adults with obesity and type 2 diabetes.
| Mean weight loss at 72 weeks with semaglutide 7.2 mg in STEP UP trials | ||
| STEP UP | STEP UP T2D | |
| Efficacy estimand* | 20.7% | 14.1% |
| Treatment-regimen estimand** | 18.7% | 13.2% |
| Categorical weight loss |
31.2% of patients achieved ≥25% weight loss |
21.3% of patients achieved ≥20% weight loss |
* Treatment effect if all people adhered to treatment, ** Treatment effect regardless of treatment adherence
About Wegovy®
Wegovy® is approved as once-daily Wegovy® pill (semaglutide tablet 25 mg) and once-weekly Wegovy® injections (semaglutide 1.7 mg, 2.4 mg and 7.2 mg) by the FDA.
Wegovy® is approved as a once-weekly injection by the EMA and by other regulatory authorities worldwide. The Wegovy® pill is currently pending marketing approval from the EMA and other regulatory authorities.
Wegovy® is indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight and in the presence of at least one weight-related comorbid condition, and approved by the FDA to reduce the risk of major adverse cardiovascular events,
such as death, heart attack or stroke in adults with known heart disease and either obesity or overweight. Furthermore, Wegovy® injection is indicated to reduce excess body weight and maintain long-term weight reduction in paediatric patients aged 12 years and older. It is approved by the FDA for the treatment of MASH in adults with moderate to advanced liver scarring (fibrosis), but not in those with cirrhosis of the liver.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Publication of inside information pursuant to Market Abuse Regulation, Article 17.
Contacts for further information
| Novo Nordisk Media: | |
| Ambre James-Brown | Liz Skrbkova (US) |
| +45 3079 9289 | +1 609 917 0632 |
| globalmedia@novonordisk.com | lzsk@novonordisk.com |
| Novo Nordisk Investors: | |
| Michael Novod | Jacob Martin Wiborg Rode |
| +45 3075 6050 | +45 3075 5956 |
| nvno@novonordisk.com | jrde@novonordisk.com |
| Sina Meyer | Max Ung |
| +45 3079 6656 | +45 3077 6414 |
| azey@novonordisk.com | mxun@novonordisk.com |
| Christoffer Sho Togo Tullin | Alex Bruce |
| +45 3079 1471 | +45 3444 2613 |
| cftu@novonordisk.com | axeu@novonordisk.com |
| Frederik Taylor Pitter | |
| +1 609 613 0568 | |
| fptr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: |
| Company announcement No 19 / 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: March 19, 2026 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |